Cargando…
Combination Therapies in Advanced, Hormone Receptor–Positive Breast Cancer
About 17% of women with breast cancer have locally advanced or metastatic disease at the time of diagnosis, and 30% to 40% of women diagnosed with early-stage disease will eventually have recurrence. The majority of breast cancers express estrogen or progesterone receptors, and hormonal therapies (H...
Autor principal: | Olson, Emily |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296414/ https://www.ncbi.nlm.nih.gov/pubmed/30564467 |
Ejemplares similares
-
Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer
por: Sammons, Sarah, et al.
Publicado: (2018) -
Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
por: Bian, Li, et al.
Publicado: (2020) -
Considerations for payers in managing hormone receptor-positive advanced breast cancer
por: Chitre, Mona, et al.
Publicado: (2014) -
Treating Elderly Patients With Hormone Receptor–Positive Advanced Breast Cancer
por: Riseberg, David
Publicado: (2015) -
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)